Schonfeld Strategic Advisors LLC Buys 381,676 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Schonfeld Strategic Advisors LLC raised its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 273.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 521,013 shares of the company's stock after acquiring an additional 381,676 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 0.32% of Neumora Therapeutics worth $5,523,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in NMRA. Northern Trust Corp lifted its position in shares of Neumora Therapeutics by 7.7% in the 4th quarter. Northern Trust Corp now owns 734,847 shares of the company's stock worth $7,789,000 after purchasing an additional 52,464 shares during the period. Rock Springs Capital Management LP raised its holdings in Neumora Therapeutics by 15.3% during the fourth quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company's stock worth $10,124,000 after purchasing an additional 127,005 shares in the last quarter. Capital International Investors raised its position in Neumora Therapeutics by 692.1% in the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company's stock worth $39,224,000 after acquiring an additional 3,233,179 shares in the last quarter. PEAK6 LLC acquired a new stake in shares of Neumora Therapeutics in the 4th quarter worth approximately $117,000. Finally, XTX Topco Ltd acquired a new stake in Neumora Therapeutics in the 4th quarter valued at $231,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Trading Up 0.9 %

Shares of NASDAQ:NMRA traded up $0.01 during trading on Thursday, reaching $0.66. 267,136 shares of the stock were exchanged, compared to its average volume of 1,484,083. The stock has a 50-day moving average price of $0.96 and a 200-day moving average price of $4.94. The firm has a market cap of $106.43 million, a PE ratio of -0.35 and a beta of 2.96. Neumora Therapeutics, Inc. has a 12 month low of $0.62 and a 12 month high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, sell-side analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on NMRA shares. HC Wainwright decreased their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Bank of America reaffirmed an "underperform" rating and set a $1.00 target price (down from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. Royal Bank of Canada reissued a "sector perform" rating and issued a $4.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Guggenheim lowered Neumora Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, March 7th. Finally, William Blair cut Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, Neumora Therapeutics presently has an average rating of "Hold" and an average target price of $9.29.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.